Vitamin Highlights

Ningxia Tairui Pharma is severely punished as long as the production is resumed without authorization.

On June 22, 2018, according to the local government's notice of suspension of production, the producing workshops of Ningxia Tairui Pharmaceutical Co., Ltd. (Tai Rui Pharma) was fully discontinued and rectified. At the same time, the Company announced and promised to fully implement the relocation plan. In mid-July, Tairui Pharma commissioned the fermenter to verify the effect of odor management. In response to the complaints from nearby residents, the Environmental Protection Inspectors promptly requested Tairui Pharma to suspend production and will further verify the company's situation. As of August 18, all seven fermenters that were resumed production were completely emptied and sealed.

Extended and updated:

1---According to the incident, the heads of both city and county level were dismissed and the other responsible officials were seriously accountable. The chairman of Tairui Pharma has been detained for alleged environmental crimes.

2---The global tylosin manufacturers are mainly Ningxia Tairui Pharmaceutical, Lukang Medicine and Qilu Pharmaceutical. Ningxia Tairui Pharma is currently the world's largest manufacturer of tylosin, with a production capacity of over 5,000 tons, and its market share of tylosin and tilmicosin is 63% and 54% respectively. The suspension of Ningxia Tairui Pharma and the limited production of Qilu Pharmaceutical have resulted in continued supply tension of tylosin, which has a seriously negative impact to the market. The prices of tylosin, tilmicosin and tiamulin will continue to go upward at high level.